BIOCIDAL POLYMERS FOR VIRAL INACTIVATION IN PLASMA

病毒污染是血浆生产和生产中的持续威胁 衍生治疗蛋白(1，2)。目前，各种不同的 有去污措施，包括巴氏杀菌法， 溶剂/洗涤剂处理和u/v照射；无一提供保证 对可能存在的各种病毒病原体的有效性(3)。 需要新的方法。N-卤胺聚合物化学研究进展 允许创建接触的杀生表面，表达快速、有效的 对流体中的细菌和病毒病原体的疗效(4，5，6)。 在这项研究中，探讨了使用这些聚合物的可行性， 灭活包膜病毒和非包膜病毒。功能性 某些血浆蛋白的保留率也将被确定。电浆 包膜和非包膜病毒的悬浮液(水泡性口炎 VSV和脑心肌炎EMCV)将通过N- 卤胺聚苯乙烯聚合物，流速和接触时间各不相同 为了建立导致6log失活所必需的参数， B)凝血因子F_9、F_8的保留率 这一过程的实际潜力。结果将被用来确定 该方法适用于范围广泛的扩展研究 病毒靶标和血浆蛋白功能，加上额外的聚合物 N-卤胺系列。 建议的商业应用： 具有可充电抗菌活性的新型杀生聚合物可 证明对灭活血浆、血浆蛋白中的病毒有效 通过转基因动物制备的制剂和治疗蛋白 技术该方法的商业应用通过流体流动或 可以为制造商和制造商开发使用聚合物的批量处理 血液制品加工机。使用这类产品可能会产生严重的 对从人血中提取的生物制剂的安全性和 动物血液或体液。

Viral contamination is a constant threat in the production of plasma and derived therapeutic proteins (1,2). Currently, a variety of decontamination measures is available, including Pasteurization, solvent/detergent treatments and u/v irradiation; none provides assurance of efficacy against the range of viral pathogens that may be present (3). New methods are needed. Recent advances in N-Halamine polymer chemistry permit creation of contact biocidal surfaces, expressing rapid, potent efficacy against bacterial and viral pathogens in fluid streams (4,5,6). In this study, the feasibility of using these polymers is explored, for inactivating both enveloped and non-enveloped viruses. Functional retention of certain plasma proteins will also be determined. Plasma suspensions of enveloped and non-enveloped viruses (Vesicular stomatitis VSV and encephalomyocarditis EMCV) will be passed through columns of N- halamine polystyrene polymers, and flow rates and contact times varied to establish a) parameters necessary to bring about a 6 log inactivation, b) retention rates of coagulation factors F IX, F VIII as indicators of the practical potential of the process. Results will be used to determine the suitability of the method for extended studies on a wide range of viral targets and plasma protein functions, with additional polymers in the N-halamine series. PROPOSED COMMERCIAL APPLICATIONS: Novel biocidal polymers with rechargeable antimicrobial activity may prove effective for inactivation of viruses in plasma, plasma protein preparations, and therapeutic proteins made through transgenic animal technology. Commercial applications of this approach by fluid stream or batch treatment with polymers could be developed for manufacturers and blood product processors. Use of such products could have a serious impact on the safety of biological agents derived from human blood and animal blood or body fluids.